JP2019501139A5 - - Google Patents

Download PDF

Info

Publication number
JP2019501139A5
JP2019501139A5 JP2018527232A JP2018527232A JP2019501139A5 JP 2019501139 A5 JP2019501139 A5 JP 2019501139A5 JP 2018527232 A JP2018527232 A JP 2018527232A JP 2018527232 A JP2018527232 A JP 2018527232A JP 2019501139 A5 JP2019501139 A5 JP 2019501139A5
Authority
JP
Japan
Prior art keywords
seq
sequence
antibody
variable region
aqueous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018527232A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019501139A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/063624 external-priority patent/WO2017091745A1/en
Publication of JP2019501139A publication Critical patent/JP2019501139A/ja
Publication of JP2019501139A5 publication Critical patent/JP2019501139A5/ja
Priority to JP2021075689A priority Critical patent/JP7157204B2/ja
Pending legal-status Critical Current

Links

JP2018527232A 2015-11-25 2016-11-23 医薬製剤及びその使用 Pending JP2019501139A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021075689A JP7157204B2 (ja) 2015-11-25 2021-04-28 医薬製剤及びその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562260104P 2015-11-25 2015-11-25
US62/260,104 2015-11-25
US201662368156P 2016-07-28 2016-07-28
US62/368,156 2016-07-28
PCT/US2016/063624 WO2017091745A1 (en) 2015-11-25 2016-11-23 Pharmaceutical formulations and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021075689A Division JP7157204B2 (ja) 2015-11-25 2021-04-28 医薬製剤及びその使用

Publications (2)

Publication Number Publication Date
JP2019501139A JP2019501139A (ja) 2019-01-17
JP2019501139A5 true JP2019501139A5 (https=) 2020-01-09

Family

ID=58763708

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018527232A Pending JP2019501139A (ja) 2015-11-25 2016-11-23 医薬製剤及びその使用
JP2021075689A Active JP7157204B2 (ja) 2015-11-25 2021-04-28 医薬製剤及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021075689A Active JP7157204B2 (ja) 2015-11-25 2021-04-28 医薬製剤及びその使用

Country Status (9)

Country Link
US (3) US20170189548A1 (https=)
EP (2) EP3380525B1 (https=)
JP (2) JP2019501139A (https=)
DK (1) DK3380525T3 (https=)
ES (1) ES2970186T3 (https=)
FI (1) FI3380525T3 (https=)
PT (1) PT3380525T (https=)
RS (1) RS65120B1 (https=)
WO (1) WO2017091745A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016285552B2 (en) * 2015-06-29 2022-10-13 Immunogen, Inc. Anti-CD123 antibodies and conjugates and derivatives thereof
EP3325482B1 (en) * 2015-07-21 2020-06-24 ImmunoGen, Inc. Methods of preparing cytotoxic benzodiazepine derivatives
KR20200070254A (ko) * 2017-09-22 2020-06-17 이뮤노젠 아이엔씨 면역접합체에서 메티오닌 산화를 방지하는 방법
CN113166053A (zh) * 2018-11-12 2021-07-23 伊缪诺金公司 制备细胞毒性苯二氮䓬衍生物的方法
MA54228A (fr) * 2018-11-12 2021-09-22 Immunogen Inc Procédés de préparation de dérivés de benzodiazépine cytotoxiques
KR20220004669A (ko) 2019-04-29 2022-01-11 이뮤노젠 아이엔씨 항-cd123 면역접합체를 포함하는 치료적 조합물
CN114667134A (zh) * 2019-08-15 2022-06-24 希沃尔拜克治疗公司 苯并氮杂䓬缀合物的制剂及其用途
IL292628A (en) 2019-11-01 2022-07-01 Magenta Therapeutics Inc Anti-cd45 antibody and conjugates accordingly
JP7735291B2 (ja) 2020-02-21 2025-09-08 エーアールエス ファーマシューティカルズ、インコーポレイテッド ネクチン-4抗体コンジュゲートおよびその使用
JP2023532304A (ja) 2020-07-01 2023-07-27 エーアールエス ファーマシューティカルズ オペレーションズ,インク. 抗asgr1抗体コンジュゲートおよびその使用
WO2026034525A1 (ja) * 2024-08-07 2026-02-12 東レ株式会社 癌の治療および/または予防用医薬組成物

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
EP0563475B1 (en) 1992-03-25 2000-05-31 Immunogen Inc Cell binding agent conjugates of derivatives of CC-1065
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
BRPI9809391B8 (pt) 1997-04-14 2021-05-25 Amgen Res Munich Gmbh processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US7067109B1 (en) 1998-07-13 2006-06-27 Board Of Regents, The University Of Texas System Cancer treatment kits comprising therapeutic conjugates that bind to aminophospholipids
CA2388063C (en) 1999-11-24 2010-06-08 Immunogen, Inc. Cytotoxic agents comprising taxanes and their therapeutic use
WO2001058479A1 (en) 2000-02-08 2001-08-16 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
NZ527283A (en) 2001-01-29 2006-03-31 Biogen Idec Inc Modified antibodies and methods of use
KR100863624B1 (ko) 2001-05-11 2008-10-15 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 Cd26을 발현하는 세포와 연관된 질환의 치료제로사용되는 항-cd26 단클론항체
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US20040161776A1 (en) * 2001-10-23 2004-08-19 Maddon Paul J. PSMA formulations and uses thereof
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
US6756397B2 (en) 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
BR0313197A (pt) 2002-08-02 2005-08-09 Immunogen Inc Agentes citotóxicos contendo potentes taxanos e seu uso terapêutico
DE60336149D1 (de) 2002-08-16 2011-04-07 Immunogen Inc Vernetzer mit hoher reaktivität und löslichkeit und ihre verwendung bei der herstellung von konjugaten für die gezielte abgabe von kleinmolekularen arzneimitteln
US20040033228A1 (en) * 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
ZA200503075B (en) 2002-11-07 2006-09-27 Immunogen Inc Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
US7834155B2 (en) 2003-07-21 2010-11-16 Immunogen Inc. CA6 antigen-specific cytotoxic conjugate and methods of using the same
ATE496944T1 (de) 2003-07-21 2011-02-15 Immunogen Inc Ca6-antigenspezifisches zytotoxisches konjugat und verfahren zu dessen anwendung
AR048098A1 (es) * 2004-03-15 2006-03-29 Wyeth Corp Conjugados de caliqueamicina
DOP2006000029A (es) * 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
WO2007019232A2 (en) * 2005-08-03 2007-02-15 Immunogen, Inc. Immunoconjugate formulations
CA2615761A1 (en) 2005-08-22 2007-03-01 Immunogen, Inc. Humanized anti-ca6 antibodies and methods of using the same
CA2790018C (en) * 2006-12-21 2015-02-03 Amgen Inc. Formulations
EP2170268A2 (en) * 2007-06-25 2010-04-07 Amgen, Inc. Compositions of specific binding agents to hepatocyte growth factor
SG189817A1 (en) 2008-04-30 2013-05-31 Immunogen Inc Potent conjugates and hydrophilic linkers
NZ610239A (en) 2008-04-30 2014-11-28 Immunogen Inc Cross-linkers and their uses
RU2683325C2 (ru) 2009-02-05 2019-03-28 Иммьюноджен, Инк. Новые производные бензодиазепина
CA2771336C (en) * 2009-09-15 2019-11-26 The Board Of Trustees Of The Leland Stanford Junior University Synergistic anti-cd47 therapy for hematologic cancers
TWI622402B (zh) 2010-02-24 2018-05-01 免疫遺傳股份有限公司 葉酸受體1抗體類和免疫共軛物類及彼等之用途
SG10201501803YA (en) 2010-03-12 2015-05-28 Immunogen Inc Cd37-binding molecules and immunoconjugates thereof
SI2528625T1 (sl) * 2010-04-15 2013-11-29 Spirogen Sarl Pirolobenzodiazepini in njihovi konjugati
BR112012033457A2 (pt) * 2010-07-02 2017-04-04 Medimmune Llc formulações de anticorpo.
JP5826863B2 (ja) 2011-02-15 2015-12-02 イミュノジェン・インコーポレーテッド 細胞傷害性ベンゾジアゼピン誘導体
ME03353B (me) 2011-03-29 2019-10-20 Immunogen Inc Priprema konjugata antitela i majtanzinoida jednostepenim postupkom
BR112013025415B1 (pt) 2011-04-01 2021-03-16 Immunogen, Inc uso de um imunoconjugado antirreceptor de folato 1 (folr1)
EP2524929A1 (en) 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
GB2516808A (en) * 2013-05-31 2015-02-11 Innova Biosciences Ltd Antibody composition and buffer system therefor
FR3008463B1 (fr) 2013-07-10 2015-08-07 Hispano Suiza Sa Structure compacte de boitier d'entrainement pour turbomachine d'aeronef
SI3071237T1 (sl) * 2013-11-21 2024-11-29 Genmab A/S Liofilizirana formulacija konjugata protitelo-zdravilo
CA2935433C (en) * 2014-01-10 2019-04-02 Synthon Biopharmaceuticals B.V. Duocarmycin anti-her2 antibody drug conjucates with activity against her2 expressing malignancies
WO2016036804A1 (en) 2014-09-03 2016-03-10 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
AU2015311987B2 (en) 2014-09-03 2020-06-04 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
SMT202000614T1 (it) * 2015-06-29 2021-01-05 Immunogen Inc Coniugati di anticorpi ingegnerizzati con cisteina
AU2016285552B2 (en) * 2015-06-29 2022-10-13 Immunogen, Inc. Anti-CD123 antibodies and conjugates and derivatives thereof

Similar Documents

Publication Publication Date Title
JP2019501139A5 (https=)
EA202091590A1 (ru) Антитела против pd-l1 и варианты их применения
JP2017536354A5 (https=)
JP2018521638A5 (https=)
JP2019535763A5 (https=)
JP2015503909A5 (https=)
EA201991099A1 (ru) Антитела против cd73 и их применение
JP2020500538A5 (https=)
RU2011105062A (ru) Нейтрализующие антитела против вируса гриппа а и их использование
FI3922645T3 (fi) Pro-/latentin myostatiinin vasta-aineita ja niiden käyttötapoja
RU2018102606A (ru) Молекулы, связывающиеся с psl pseudomonas, и пути их применения
EA201190132A1 (ru) Гуманизированные антитела, связывающиеся с cd19, и их применение
NZ625403A (en) Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
JP2010536384A5 (https=)
JP2014511179A5 (https=)
JP2018536393A5 (https=)
JP2017528476A5 (https=)
JP2014512809A5 (https=)
JP2017533694A5 (https=)
RU2014101707A (ru) АНТИ-Axl АНТИТЕЛА И ИХ ПРИМЕНЕНИЕ
RU2010123888A (ru) Axl-антитела
JP2016513682A5 (https=)
RU2018135371A (ru) АНТИТЕЛА К ФАКТОРУ КОМПЛЕМЕНТА Bb
RU2016100892A (ru) Антитела против tweakr и их применение
RU2019119862A (ru) Антитела к компоненту комплемента c5